Price dynamics of trifluridine tipiracil (Lansifer) in 2024

Trifluridine and tipiracil (Lonsurf), a compound preparation containing two active ingredients: trifluridine and tipiracil, plays an important role in the treatment of metastatic colorectal cancer. This drug has become an important treatment option, especially for adult patients who have already undergone chemotherapy regimens with fluoropyrimidine, oxaliplatin, and irinotecan. In addition to this, it also plays a role in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma in certain conditions.

In the Chinese market, this original drug is sold as"Trifluridine Tipiracil Tablets" or "Langsifu". Although it has been launched on the market, it is not yet included in the national medical insurance coverage. Depending on the specifications, such as the common 15mg*20 tablets and 20mg*20 tablets, the price may fluctuate around 6,000 yuan. At the same time, if consumers choose to buy the Hong Kong version of this drug, they may face a higher price, about more than 10,000 yuan, which will also be affected by exchange rate changes. Domestic generic versions of trifluridine and tipiracil are already on the market and included in the scope of medical insurance. Their prices are relatively low, probably around 2,000 yuan, which greatly reduces the financial burden on patients.

In addition to the domestic market, overseas versions of this drug also have their own specific price ranges. For example, the price of the Japanese version of the original drug in overseas markets is about more than more than 5,000 yuan. In addition, for some patients looking for more affordable options, cheaper generic drugs are available in overseas markets. The ingredients of these generic drugs are basically the same as the original drugs, but the prices are more affordable. Taking the version produced by an Indian pharmaceutical factory as an example, its price may only be more than 1,000 yuan. Of course, this price will also be affected by exchange rate changes.